M&T Bank
CCCC icon

M&T Bank’s C4 Therapeutics CCCC Stock Holding History

M&T Bank’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-132,715
Closed -$478K – 1573
2024
Q4 		$478K Buy
132,715
+18,808
+17% +$93.5K ﹤0.01% 1188
2024
Q3 		$649K Buy
113,907
+18,466
+19% +$111K ﹤0.01% 1066
2024
Q2 		$441K Buy
95,441
+10,631
+13% +$63.4K ﹤0.01% 1167
2024
Q1 		$692K Sell
84,810
-53,778
-39% -$417K ﹤0.01% 1013
2023
Q4 		$784K Sell
138,588
-1,432
-1% -$3.27K ﹤0.01% 961
2023
Q3 		$260K Buy
+140,020
New +$427K ﹤0.01% 1329
2023
Q2 		– Sell
-72,000
Closed -$226K – 1654
2023
Q1 		$226K Buy
72,000
+10,708
+17% +$63K ﹤0.01% 1416
2022
Q4 		$362K Buy
61,292
+10,142
+20% +$84.1K ﹤0.01% 1224
2022
Q3 		$448K Sell
51,150
-10,844
-17% -$113K ﹤0.01% 1134
2022
Q2 		$468K Buy
61,994
+44,646
+257% +$393K ﹤0.01% 1036
2022
Q1 		$420K Buy
17,348
+9,944
+134% +$241K ﹤0.01% 1062
2021
Q4 		$238K Buy
7,404
+1,447
+24% +$57.2K ﹤0.01% 1367
2021
Q3 		$266K Sell
5,957
-41
-0.7% -$1.76K ﹤0.01% 1295
2021
Q2 		$227K Buy
+5,998
New +$215K ﹤0.01% 1399

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

M&T Bank's CCCC Position: Q1 2025 in Review

M&T Bank sold out of C4 Therapeutics (CCCC) in Q1 2025, closing a stake of 132,715 shares — an estimated $478K sold.

M&T Bank first reported a position in CCCC in Q2 2021 and held it in 14 quarters. The position peaked at $784K in Q4 2023. 114 funds tracked by Wall St. Rank hold CCCC as of Q1 2025.

  • M&T Bank reported no remaining C4 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • M&T Bank sold 132,715 C4 Therapeutics shares in Q1 2025, an estimated $478K.
  • M&T Bank first reported a position in C4 Therapeutics in Q2 2021 and held it in 14 quarters.
  • M&T Bank's C4 Therapeutics position peaked at $784K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2025.

Based on M&T Bank's 13F filing for Q1 2025, filed 30 Apr 2025.